Europe Continuous Glucose Monitoring Systems Market – Opportunities and Forecasts, 2014 – 2021

Date: 2016-03

“Continuous glucose monitoring system (CGMS) is a device that provides with the real-time glucose monitoring in diabetes patients. This technology helps diabetes patients to track their glucose levels round-the-clock. CGMS devices monitor glucose levels at an interval of every 5 minutes. CGMS devices are used along with blood glucose meters to provide supplementary information to facilitate better glucose monitoring and treatment. This technology can be used in diabetes type 1 as well as diabetes type 2 patients. Continuous glucose monitoring assist in stabilizing elevated A1C levels, thereby, reducing the risk of developing long-term diabetic complications. The adoption of CGMS technology is expected to increase, owing to its application in artificial/bionic pancreas.

The Europe CGMS market is estimated to garner $351.7 million by 2021, registering a CAGR of 38.0% during the forecast period. This market is expected to witness significant growth from 2015 to 2021, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increasing incidence of diabetes cases in Europe, increasing per capita healthcare expenditure, and growing purchasing power on account of high disposable income of individuals have fueled the market growth. Furthermore, ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring has supplemented the market growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and limited awareness about CGMS among patients are the major factors hampering the growth of the market.

The report segments the Europe CGMS market on the basis of country and components. Based on country, the market is segmented into the U.K., France, Germany, Norway, Sweden, Denmark, Finland and Other Europe. Presently, the Germany leads the Europe CGMS market, owing to its large diabetes patient pool and high healthcare expenditure. The components of the CGMS comprise sensors, transmitters & receivers, and integrated insulin pumps. The sensors segment dominates the market, as the sensor loses its sensitivity after using if for about 5 to 7 days, which requires frequent requirement.

Europe CGMS market has presence of numerous manufacturers that are adopting partnership and collaboration as their strategy to commercialize CGMS. For instance, Senseonics and Rubin Medical have adopted the collaboration strategy to commercialize their CGMS products in Denmark and Sweden. The companies profiled in the report include Medtronic Inc., Dexcom, Inc., Abbott Diabetic care, Senseonics Incorporated, Insulet Corporation, Echo therapeutics, Glysens Inc. and Animas Corporation,


This report provides an in-depth analysis of the current and emerging market trends and dynamics in the Europe CGMS market.
The European CGMS market is analyzed based on countries such as the U.K., France, Germany, Norway, Sweden, Denmark, Finland, and Other Europe.
An in-depth analysis of key strategies adopted by key manufacturers helps in understanding competitive scenario.
This report provides an exhaustive analysis of the factors that drive and restrict the growth of the Europe CGMS market.
The reimbursement scenario of CGMS devices has been provided in this report.


Other Europe

Transmitters & receivers
Integrated insulin pumps”

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample